A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States

References

• Centers for Disease Control and Prevention (CDC). RSV in infants and young children; 2022 Oct 28 [accessed 2023 May 26]. https://www.cdc.gov/rsv/high-risk/infants-young-children.html.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Increased interseasonal respiratory syncytial virus (RSV) activity in parts of the southern United States. 2021 June 10 [accessed 2023 May 26]. https://emergency.cdc.gov/han/2021/han00443.asp.
   Google Scholar
• Abbasi J. “This is our COVID”-what physicians need to know about the pediatric RSV surge. JAMA. 2022;328(21):2096–13. doi:10.1001/jama.2022.21638.
   Web of Science ®Google Scholar
• Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022 Mar 3. 386(9):837–46. doi:10.1056/NEJMoa2110275.
   PubMed Web of Science ®Google Scholar
• Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, Baker J, Pérez Marc G, Radley D, Shittu E, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023 Apr 20. 388(16):1451–64. doi:10.1056/NEJMoa2216480.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). FDA approves first vaccine for pregnant individuals to prevent RSV in infants; 2023 Aug 21 [accessed 2023 Nov 13]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants#:~:text=Abrysvo%20is%20approved%20for%20use,years%20of%20age%20and%20older.
   Google Scholar
• Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sánchez PJ, Kotton CN, Mahon BE, Meyer S, Long SS, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the advisory committee on immunization practices — United States. MMWR Morb Mortal Wkly Rep. 2023;72(34):920–5. doi:10.15585/mmwr.mm7234a4.
   PubMed Web of Science ®Google Scholar
• Dudley MZ, Limaye RJ, Omer SB, O’Leary ST, Ellingson MK, Spina CI, Brewer SE, Chamberlain AT, Bednarczyk RA, Malik F, et al. Characterizing the vaccine knowledge, attitudes, beliefs, and intentions of pregnant women in Georgia and Colorado. Hum Vaccin Immunother. 2020 May 3;16(5):1109–17. doi:10.1080/21645515.2020.1717130.
   PubMed Web of Science ®Google Scholar
• Skirrow H, Barnett S, Bell S, Riaposova L, Mounier-Jack S, Kampmann B, Holder B. Women’s views on accepting COVID-19 vaccination during and after pregnancy, and for their babies: a multi-methods study in the UK. BMC Pregnancy Childbirth. 2022 Jan 14;22(1):33. doi:10.1186/s12884-021-04321-3.
   PubMed Web of Science ®Google Scholar
• Dudley MZ, Limaye RJ, Salmon DA, Omer SB, O’Leary ST, Ellingson MK, Spina CI, Brewer SE, Bednarczyk RA, Malik F, et al. Racial/ethnic disparities in maternal vaccine knowledge, attitudes, and intentions. Public Health Rep. 2021;136(6):699–709. doi:10.1177/0033354920974660.
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Law AW, Maculaitis MC, Will O, Kopenhafer L, Olsen P, Hauber B, Vietri JT, Cappelleri JC, Coulter JR, et al. Healthcare providers’ and pregnant people’s preferences for a preventive to protect infants from serious illness due to respiratory syncytial virus. Vaccines (Basel). 2024;12(5):560. doi:10.3390/vaccines12050560.
   PubMed Web of Science ®Google Scholar
• Orme B. Getting started with conjoint analysis: strategies for product design and pricing research. 4th ed. Madison (WI): Research Publishers LLC; 2019.
   Google Scholar
• Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomic. 2019;37(2):201–26. doi:10.1007/s40273-018-0734-2.
   PubMed Web of Science ®Google Scholar
• Michaels-Igbokwe C, MacDonald S, Currie GR. Individual preferences for child and adolescent vaccine attributes: a systematic review of the stated preference literature. Patient. 2017;10(6):687–700. doi:10.1007/s40271-017-0244-x.
   PubMedGoogle Scholar
• Wang Y, Wang Z, Wang Z, Li X, Pang X, Wang S. Application of discrete choice experiment in health care: a bibliometric analysis. Front Public Health. 2021 June 4;9:673698. doi:10.3389/fpubh.2021.673698.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus infection (RSV). 2022 Oct 28 [accessed 2023 May 26]. https://www.cdc.gov/rsv/index.html.
   Google Scholar
• Etti M, Calvert A, Galiza E, Lim S, Khalil A, Le Doare K, Heath PT. Maternal vaccination: a review of current evidence and recommendations. Am J Obstet Gynecol. 2022 Apr;226(4):459–74. doi:10.1016/j.ajog.2021.10.041.
   PubMed Web of Science ®Google Scholar
• Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020 Jul 30;383(5):415–25. doi:10.1056/NEJMoa1913556.
   PubMed Web of Science ®Google Scholar
• Muňoz FM, Swamy GK, Hickman SP, Agrawal S, Piedra PA, Glenn GM, Patel N, August AM, Cho I, Fries L, et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis. 2019 Oct 22;220(11):1802–15. doi:10.1093/infdis/jiz390.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). WHO preferred product characteristics for respiratory syncytial virus (RSV) vaccines. 2017 [accessed 2022 Mar 24]. https://www.who.int/publications/i/item/WHO-IVB-17.11.
   Google Scholar
• Schwarz TF, Johnson C, Grigat C, Apter D, Csonka P, Lindblad N, Nguyen TLA, Gao FF, Qian H, Tullio AN, et al. Three dose levels of a maternal respiratory syncytial virus vaccine candidate are well tolerated and immunogenic in a randomized trial in nonpregnant women. J Infect Dis. 2022 June 15;225(12):2067–76. doi:10.1093/infdis/jiab317.
   PubMed Web of Science ®Google Scholar
• Baral R, Higgins D, Regan K, Pecenka C. Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model. BMJ Open. 2021 Apr 24;11(4):e046563. doi:10.1136/bmjopen-2020-046563.
   PubMed Web of Science ®Google Scholar
• Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. Fam Med. 2004 Sep;36(8):588–94.
   PubMed Web of Science ®Google Scholar
• Hauber AB, González JM, Groothuis-Oudshoorn CG, Prior T, Marshall DA, Cunningham C, IJzerman MJ, Bridges JFP. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016 June;19(4):300–15. doi:10.1016/j.jval.2016.04.004.
   PubMed Web of Science ®Google Scholar
• Boeri M, Saure D, Schacht A, Riedl E, Hauber B. Modeling heterogeneity in patients’ preferences for psoriasis treatments in a multicountry study: a comparison between random-parameters logit and latent class approaches. Pharmacoeconom. 2020;38(6):593–606. doi:10.1007/s40273-020-00894-7.
   PubMed Web of Science ®Google Scholar
• Vass C, Boeri M, Karim S, Marshall D, Craig B, Ho K-A, Mott D, Ngorsuraches S, Badawy SM, Mühlbacher A, et al. Accounting for preference heterogeneity in discrete-choice experiments: an ISPOR special interest group report. Value in Health. 2022;25(5):685–94. doi:10.1016/j.jval.2022.01.012.
   PubMed Web of Science ®Google Scholar
• Zhou M, Thayer WM, Bridges JFP. Using latent class analysis to model preference heterogeneity in health: a systematic review. Pharmacoeconom. 2018;36(2):175–87. doi:10.1007/s40273-017-0575-4.
   PubMed Web of Science ®Google Scholar
• Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc Series B Stat Methodol. 1977;39(1):1–22. doi:10.1111/j.2517-6161.1977.tb01600.x.
   Web of Science ®Google Scholar
• Raftery AE. Bayesian model selection in social research. Sociol Methodol. 1995;25:111–63. doi:10.2307/271063.
   Web of Science ®Google Scholar
• Rosner B. Fundamentals of biostatistics. 8th ed. Boston (MA): Cengage Learning; 2015.
   Google Scholar
• Kwak C, Clayton-Matthews A. Multinomial logistic regression. Nurs Res. 2002;51(6):404–10. doi:10.1097/00006199-200211000-00009.
   PubMed Web of Science ®Google Scholar
• Bendel RB, Afifi AA. Comparison of stopping rules in forward “stepwise” regression. J Am Stat Assoc. 1977;72(357):46–53. doi:10.1080/01621459.1977.10479905.
   Web of Science ®Google Scholar
• Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129(1):125–37. doi:10.1093/oxfordjournals.aje.a115101.
   PubMed Web of Science ®Google Scholar
• Gidengil C, Jones J, Pike J, Prill M, Wodi P, Lindley M, Gedlinske A, Parker A, Scherer A. Willingness to receive maternal RSV vaccine and infant monoclonal RSV antibody. Poster presented at the Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) Annual Meeting; 2023 Jul 27–29; Denver, CO, USA.
   Google Scholar
• Hoogink J, Verelst F, Kessels R, Van Hoek AJ, Timen A, Willem L, Beutels P, Wallinga J, De Wit GA. Preferential differences in vaccination decision-making for oneself or one’s child in the Netherlands: a discrete choice experiment. BMC Public Health. 2020;20(1):828. doi:10.1186/s12889-020-08844-w.
   PubMed Web of Science ®Google Scholar
• Lavelle TA, Messonnier M, Stokley S, Kim D, Ramakrishnan A, Gebremariam A, Simon NJE, Rose AM, Prosser LA. Use of a choice survey to identify adult, adolescent and parent preferences for vaccination in the United States. J Patient Rep Outcomes. 2019;3(1):51. doi:10.1186/s41687-019-0135-0.
   PubMedGoogle Scholar
• Treskova M, Pozo-Martin F, Scholz S, Schönfeld V, Wichmann O, Harder T. Assessment of the effects of active immunisation against respiratory syncytial virus (RSV) using decision-analytic models: a systematic review with a focus on vaccination strategies, modelling methods and input data. Pharmacoeconomics. 2021;39(3):287–315. doi:10.1007/s40273-020-00991-7.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Limited availability of nirsevimab in the United States—interim CDC recommendations to protect infants from respiratory syncytial virus (RSV) during the 2023–2024 respiratory virus season. 2023 Oct 23 [accessed 2023 Dec 14]. https://emergency.cdc.gov/han/2023/han00499.asp.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). National vital statistics reports - births: final data for 2020. 2022 Jul 2 [accessed 2023 Mar 25]. https://stacks.cdc.gov/view/cdc/112078.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). National vital statistics reports - natality on CDC WONDER online database 2016-2021. 2022 June 17 [accessed 2023 Mar 25]. http://wonder.cdc.gov/natality-expanded-current.html.
   Google Scholar